Expert Review of Respiratory Medicine

Papers
(The H4-Index of Expert Review of Respiratory Medicine is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis180
Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2175
False-positive and false-negative COVID-19 cases: respiratory prevention and management strategies, vaccination, and further perspectives80
Pulmonary fibrosis secondary to COVID-19: a narrative review61
Extrapulmonary tuberculosis55
Artificial intelligence and machine learning in respiratory medicine52
Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis44
Reported quality of life in countries with cases of COVID19: a systematic review41
Rehabilitation of patients with COVID-1939
Diagnostic approaches in COVID-19: clinical updates39
Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential39
Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19: a rapid systematic review and meta-analysis35
The long-lasting effects of the acute respiratory distress syndrome32
The COVID-19 pandemic: a target for surfactant therapy?31
Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review30
Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies29
Role of fever and ambient temperature in COVID-1929
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management29
Endobronchial valve therapy for severe emphysema: an overview of valve-related complications and its management28
Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study28
An overview of the available treatments for chronic cavitary pulmonary aspergillosis27
COPD patients in a COVID-19 society: depression and anxiety25
Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients25
Ten challenging questions about SARS-CoV-2 and COVID-1924
0.092350006103516